Maritoclax
CAS: 1227962-62-0
Ref. 3D-CZB96262
| 5mg | To inquire | |
| 10mg | To inquire | |
| 25mg | To inquire | |
| 50mg | To inquire | |
| 100mg | To inquire |
Product Information
- 1,1'-(4,4',5,5'-Tetrachloro[1,3'-bi-1H-pyrrole]-2,2'-diyl)bis[1-(2-hydroxyphenyl)methanone]
Maritoclax is a low-potency, selective inhibitor of the mcl-1 protein. It has been shown to increase the sensitivity of leukemia cells to chemotherapy by inducing apoptosis in leukemia cells that express wild-type mcl-1 and chemoresistance in those that have mutated the protein. Maritoclax has also been shown to be effective against skin cancer in vivo, where it inhibits proliferation and induces apoptosis. In addition, maritoclax can induce apoptosis in primary cells from human patients with autoimmune diseases such as systemic lupus erythematosus.
Mutations in cyclin D2 may lead to resistance to maritoclax treatment because the drug only works on cells with wild-type cyclin D2 expression. This drug may also be synergistic with other drugs that target cell proliferation, such as gemcitabine or cetuximab.
Chemical properties
Technical inquiry about: 3D-CZB96262 Maritoclax
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
